Credit: Ascannio/Shutterstock.com

Inovio Pharmaceuticals, Inc. (INO) stock was down by 14% over the past month. The reason may be related to the company's delay of its Covid-19 vaccine candidate, the phase 2 trial of INO-4800. The company expects that the completing its Phase 2 segment in the second quarter of 2021 and seeking to advance to the Phase 3 portion of the trial. Investors may think that its candidate drug will be too late in the market, but the things around the Covid-19 vaccine may be not simple like that. In fact, Inovio still has a chance.

INOVIO said in its Q4 2020 report that it has been closely monitoring the development and evolution of SARS-CoV-2 (which causes COVID-19) mutations, with a particular focus on the UK, South African and Brazilian variants. With instances of these variants on the rise globally, the emergence and the spread of the variants have been an area of high priority for INOVIO.

INOVIO is currently evaluating the impact of newly circulating strains of the SARS-CoV-2 virus on the immune profile of INO-4800 through an assessment of binding antibodies, neutralizing antibodies in both live and pseudo assays. At the same time, INOVIO is also developing next-generation, pan-COVID vaccine candidates that could be tailored to the known and potentially unknown SAR-CoV-2 variants.

INOVIO also entered into a collaboration and license agreement for INO-4800 with Advaccine, who will have the exclusive right to develop, manufacture and commercialize INO-4800 within Greater China. INOVIO has received an upfront payment of $3.0 million and is eligible to receive up to an aggregate of $108.0 million upon the achievement of specified development and sales-based milestones for INO-4800 in Greater China.

Currently, the demand for Covid-19 vaccine is extremely high across the globe, INOVIO still has a chance and time to acquire success with INO-4800. But the important thing for investors is to find timing to invest. At present, there are six wall street analysts have rated the stock in the last three months and its average price target is $17.20, which is 97% upside potential.

Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.